Johnson & Johnson Enterprise Innovation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Johnson & Johnson Enterprise Innovation sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 6 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Johnson & Johnson Enterprise Innovation: 7 sponsored US clinical trials, 6 recruiting.

Johnson & Johnson Enterprise Innovation sponsors 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Non-Small Cell Lung, with 2 trials.

Upper-quartile sponsor footprint

Johnson & Johnson Enterprise Innovation sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

A Study of JNJ-1761981 in Participants With Solid Tumors

NCT07525141
RECRUITING Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212
RECRUITING Phase 2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908
RECRUITING Phase 1

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578
RECRUITING Phase 1

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786
RECRUITING Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173
COMPLETED NA

Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy

NCT05231278

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1
Phase 3 1

Therapeutic Areas

Carcinoma, Non-Small Cell Lung 2
Aged 1
Squamous Cell Carcinoma of Head and Neck 1
Locally Advanced Head and Neck Squamous Cell Carcinoma 1
Neoplasms 1

What is open in the Johnson & Johnson Enterprise Innovation pipeline

6 recruiting of 7 indexed (86% open); 1 completed (14%).

Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Carcinoma, Non-Small Cell Lung (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Johnson & Johnson Enterprise Innovation: open-pipeline peers nationwide

Peers matched on 7 registered trials and 86% open enrollment, not the therapeutic-area sidebar.

Johnson & Johnson Enterprise Innovation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 5.566.577.5 0%20%40%60%80%100% Total trials Recruiting share Johnson & Johnson Enterprise Innovation3M4Life Research89bioAbbott Diagnostics DivisionMediLink Therapeutics (Suzhou) Co.Centessa Pharmaceuticals (UK) LimitedMeyer Children's Hospital IRCCSSystImmune
Johnson & Johnson Enterprise Innovation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Johnson & Johnson Enterprise Innovation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 86% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Johnson & Johnson Enterprise Innovation page

7 registered trials is a research-attention snapshot, not an endorsement of Johnson & Johnson Enterprise Innovation or any single study.

  • 6 of Johnson & Johnson Enterprise Innovation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Carcinoma, Non-Small Cell Lung is the condition Johnson & Johnson Enterprise Innovation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Non-Small Cell Lung trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Johnson & Johnson Enterprise Innovation pipeline card: 7 registered trials from official public datasets.Report a data error.